Past February 23, 2023, our colleague Dr. Natalia Fernández Bertólez assisted to the 2nd CA17140 Nano2Clinic Short-Term Scientific Mission Virtual Conference. She performed two oral communications about the “Evaluation and validation of the suitability of the standardized in vitro mammalian cell Micronucleus (MN) test (OECD TG No. 487) for testing genotoxicity of nanodrugs with potential use in cancer nanomedicine” and the “Biocompatibility evaluation of CeO2 nanoparticles to be employed as nanodrugs in brain cancer nanomedicine”, both based upon works from COST Action CA17140 “Cancer Nanomedicine from the Bench to the Bedside” supported by COST (European Cooperation in Science and Technology).
This last STSM conference was a great success, with more than 110 attendees from all over the world. That was an important opportunity for NanoToxGen Group to share the main outcomes of their recent works with an expert and wide audience in Nanoscience, Nanotoxicology and Nanomedicine.
Great job!
The Conference Book of Abstracts (BOA) (https://doi.org/10.18778/CostAction17140) is also available for download on this page.